# Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

> **NCT07156253** · PHASE1 · RECRUITING · sponsor: **Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd** · enrollment: 110 (estimated)

## Conditions studied

- Metastatic Solid Tumor
- Ovarian Cancer
- Breast Cancer
- BRCA 1 /2 and / or HRD
- Advanced Solid Tumors

## Interventions

- **DRUG:** SYN818 and Olaparib will be administered

## Key facts

- **NCT ID:** NCT07156253
- **Lead sponsor:** Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-26
- **Primary completion:** 2028-08-25
- **Final completion:** 2029-02-25
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07156253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07156253, "Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07156253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*